Skip to content
ppharmaranks
Menu

synribo

Pharmaranks rates Synribo 2.8/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Synribo (Omacetaxine Mepesuccinate) is a medication supplied as a powder.

Omacetaxine Mepesuccinate · by Teva

56/100Limited · 1 source

Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate
Verified againstopenFDANIH DailyMedRxClass

Key facts

Active ingredient
Omacetaxine Mepesuccinate
Form
Powder
Strength
Omacetaxine Mepesuccinate 3.5MG/VIAL
Type
Prescription (Rx)
Brand or generic
Brand-name
Manufacturer
Teva
FDA application
NDA203585
Availability
Discontinued (per FDA)

Dosage forms

Powder

The forms currently marketed in the U.S., per the FDA National Drug Code Directory.

Ways to save

Ask for the generic

Same active ingredient, far cheaper. Is there a generic? →

Request a 90-day supply

Bulk fills usually lower the per-dose price vs monthly refills.

Use copay cards

Manufacturer copay cards & patient-assistance programs — especially for brand drugs.

Compare alternatives

A same-class option may cost less. See alternatives →

Frequently asked questions

How is Synribo rated?
pharmaranks gives Synribo a composite score of 2.8 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
Is there a coupon or discount for Synribo?
pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Synribo. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
Who makes Synribo?
Synribo is marketed by Teva. You can see Teva's full profile, rating, and other products on pharmaranks.
Is Synribo a brand-name or generic drug?
Synribo is a brand-name product with the active ingredient Omacetaxine Mepesuccinate.
Is Synribo available over the counter?
No. Synribo is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
What forms does Synribo come in?
Synribo is currently marketed as powder, per the FDA's National Drug Code Directory.
Is Synribo FDA-registered?
Synribo is on record with the U.S. FDA under application number NDA203585. You can verify this on its official FDA label.
Has Synribo been recalled by the FDA?
Synribo has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
Is Synribo safe?
There's no single safe-or-not verdict. pharmaranks gives Synribo a recall-safety score of 56/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.

Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.

Reviews

No reviews yet. Be the first to write one.

Write a review

Reviews are user opinions, not medical advice. Consult a licensed professional.

People also viewed

Compare Synribo head-to-head

Identify a pill by its imprint →Check a drug interaction →Drug recalls →

Browse medications A–Z

Research products from A to Z, compare independent ratings, and find alternatives.